Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 12/20 | 0.47 |
| ▸ | HTR6 | P50406 | 3/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL818607 | 1.00 | PLA2G2A (0.47) | PLA2G2AHTR6PSEN1PSEN2APH1B | |
| Water SCHEMBL6979476 | 0.99 | PLA2G2A (0.48) | PLA2G2AHTR6PSEN1PSEN2APH1B | |
| SCHEMBL29862401 | 0.92 | PLA2G2A (0.53) | PLA2G2AHTR6 | |
| SCHEMBL818313 | 0.92 | PLA2G2A (0.53) | PLA2G2AHTR6 | |
| SCHEMBL6699396 | 0.85 | PLA2G2A (0.48) | PLA2G2AHTR6 | |
| SCHEMBL6695314 | 0.84 | HTR6 (0.41) | PLA2G2AHTR6 | |
| SCHEMBL819058 | 0.82 | PLA2G2A (0.61) | PLA2G2AHTR6 | |
| SCHEMBL819415 | 0.82 | PLA2G2A (0.51) | PLA2G2AHTR6 | |
| SCHEMBL29862597 | 0.82 | PLA2G2A (0.51) | PLA2G2AHTR6 | |
| SCHEMBL29862369 | 0.82 | PLA2G2A (0.51) | PLA2G2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3448378-B1 | PLA2 AND HMG-COA INHIBITORS FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSING HEMOLYSIS, CEREBRAL EDEMA, AND ACUTE KIDNEY INJURY | OPHIREX INC (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-116585306-A | PLA2 inhibitors for immediate treatment of hymenoptera toxicity and other conditions due to histamine release | 奥菲瑞克斯股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-109562098-B | PLA2 inhibitors for immediate treatment of hymenoptera toxicity and other conditions due to histamine release | 奥菲瑞克斯股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115379836-A | Early management and prevention of sepsis and sepsis-like syndrome | 奥菲瑞克斯公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-4045026-A1 | EARLY MANAGEMENT AND PREVENTION OF SEPSIS AND SEPSIS-LIKE SYNDROMES | Ophirex, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |